Milestone Scientific: Revolutionizing the Subcutaneous Drug Delivery Process
Follow Milestone Scientific on :
Dr. Mark Hochman, Clinical Director
Headquartered in New Jersey, Milestone Scientific has embarked on the mission of revolutionizing the way that medical injections are performed with its CompuFlo®-Epidural System using Dynamic Pressure Sensing® (DPS®) technology. With traditional syringe based systems, clinicians are unable to control and monitor both flow rate and fluid pressure during subcutaneous drug delivery. This leads to several difficulties in syringe control while rendering the entire injection procedure as an uncertain and uncomfortable event for most patients. Contrary to this, Milestone Scientific’s patented technology equips anesthesiologists and other clinicians with the ability to control the drug administration rate and precisely monitor and control the fluid pressure at the orifice of the needle in real-time on a continuous basis. Not stopping there, the DPS technology enables clinicians to rightly identify specific targets by discriminating between different tissue types and anatomic locations. Based on monitoring pressure measurements during the injection process, enables one to administer subcutaneous drugs more effectively. “Being microprocessor driven, our system presents clinical information both in visual and acoustical formats thus enabling procedures to be performed as a new enhanced experience,” asserts Dr. Mark Hochman, Clinical Director, Milestone Scientific.
He mentions that the DPS technology can be used for many medical applications like Epidural Block regional anesthesia techniques, which is commonly used for surgery, obstetrics, and postoperative pain management. Successful identification of the epidural space (ES) is an integral part of regional anesthesia. Although the ES determination process can be performed in various ways, the loss of resistance (LOR) syringe technique is the most common. However, the process bases mostly on the efficiency and expertise of anesthesiologists. As such, instances are not uncommon of false loss of resistance or misidentification of the epidural space resulting in inadequate or failed epidural blocks. “The CompuFlo® Epidural System allows clinicians to identify the epidural space with high precision and can differentiate between the true loss of resistance and the false loss of resistance more efficiently and effectively as shown in a recently published study.”
Dr. Hochman remarks. Milestone Scientific’s patented technology has proved its value proposition during a multi-center, prospective randomized controlled noninferiority trial conducted with 400 patients. Included in this study where a subset of patients with a high body mass index (BMI) (29.9 ± 6.62). The outcomes of the study were intriguing, to say the least. Researchers witnessed a 99 percent success rate for ES identification using the CompuFlo®- Epidural system. “We have already received FDA approval and CE mark for our product and commercially rolling it out across the globe,” Dr. Hochman says.
Being microprocessor driven, our system presents clinical information both in visual and acoustical formats thus enabling procedures to be performed as a new enhanced experience.
Building on the scope of DPS technology, Dr. Hochman and his team have developed and integrated CathCheckTM into the existing system. It provides physicians and nurses with the opportunity to monitor the presence or absence of a specific pressure waveform that is used to help determine location of either a needle or catheter. They can understand if the needle or catheter is in the right place or has been dislocated from the ES with this information.
Experts at Milestone Scientific are doing continuous research to expand the reach of their novel DPS technology. For instance, it can open up new windows for cosmetic procedures by letting clinicians more easily maintain optimal pressure while Botulinum Toxin injections. Apart from it, technology may play a significant role in streamlining ophthalmic injections, general medical injections, and self-administered injections.
“Our goal is to change the art and science of subcutaneous injections so that there is greater predictability for clinicians and reduced pain and anxiety for our patients. Thus improving outcomes while reducing costs. We have developed several commercially available products that speak to these objectives. We are already well established in the dental market because The Wand®/Single Tooth Anesthesia® (STA®) System that for years has been allowing dental professionals to perform virtually painless dental injections. And as we move forward, we are confident we will reach new heights of success with many new innovative products,” Dr. Hochman concludes.